Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer: Observational Retrospective Analysis

NCT02790320 is registered in ClinicalTrials.gov with Eisai Farmacêutica S.A. as lead sponsor.

NCT NCT02790320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02790320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer: Observational Retrospective Analysis
Lead sponsor
Eisai Farmacêutica S.A.
Phase
Observational
Overall status
Completed
Start date
June 30, 2012
Completion date
November 30, 2012
Enrollment
112 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer